Streetbeat News

Stock Prices

RVNC

Analysts have provided bullish ratings for Revance Therapeutics (NASDAQ:RVNC) in the last quarter. The average price target is $34.33, implying an upside from the current price of $13.81. However, this represents an 8.04% decrease from the previous average price target of $37.33.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 12:00 pm

ENVB

EYEN

PRCH

Insiders at Eyenovia, Inc. (EYEN), Enveric Biosciences, Inc. (ENVB), and Porch Group, Inc. (PRCH) have recently acquired shares, indicating their confidence in the companies' prospects. EYEN's CEO bought 2,537 shares at an average price of $1.70, following a $12 million registered direct offering. ENVB's Director purchased 1,000 shares at an average price of $2.14, after the company filed a provisional patent application for AI-based computational methods. PRCH's Director, CEO, Chairman, and Founder acquired 86,373 shares at an average price of $0.83, despite the company posting a wider-than-expected quarterly loss.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 11:58 am

NIO

Nio, Inc. (NYSE:NIO) shares were advancing in premarket trading on Wednesday, following a 17.07% plunge in the previous session. The company announced plans to offer $1 billion in convertible senior notes in two parts, with the proceeds to be used for repurchasing existing debt securities and strengthening its balance sheet. Despite the capital raise not involving the sale of additional shares, the stock was hammered on Tuesday. European registration data showed Nio sold 46 European cars in September.

Portfolio Pulse from Shanthi Rexaline

September 20, 2023 | 11:51 am

SPRY

ARS Pharma's shares are trading lower following the FDA's Complete Response Letter for the company's neffy epinephrine nasal spray, requesting additional study.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 11:51 am

AMAM

FYBR

WEST

Insider trades were noted in Westrock Coffee Company (NASDAQ:WEST), Ambrx Biopharma Inc. (NASDAQ:AMAM), and Frontier Communications Parent, Inc. (NASDAQ:FYBR). Westrock's Director acquired shares worth around $18.77 million, despite the company posting downbeat Q2 results. Ambrx's 10% owner acquired shares worth around $19.63 million, following Cantor Fitzgerald's reiteration of an Overweight rating and a $25 price target. Ares Partners Holdco LLC, a 10% owner of Frontier Communications, bought shares worth around $1.48 million, even as JP Morgan lowered the price target from $35 to $33.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 11:50 am

BAC

Bank of America's CFO, Alastair Borthwick, stated at a conference that elevated consumer buying behavior is still noticeable. He also mentioned that it's difficult to foresee a U.S. recession when consumer spending is 4% higher year-over-year.

Portfolio Pulse from Charles Gross

September 20, 2023 | 11:41 am

SEEL

Seelos Therapeutics announced that its SLS-002 study did not meet the pre-defined primary endpoint due to the limited sample size.

Portfolio Pulse from Charles Gross

September 20, 2023 | 11:29 am

SPY

USO

A recent headline from Benzinga stating that U.S. President Biden is considering depleting the Strategic Petroleum Reserve was incorrectly attributed to The Wall Street Journal and did not originate from President Biden.

Portfolio Pulse from Charles Gross

September 20, 2023 | 11:26 am

ACN

MSFT

PSO

ZUO

Pearson Plc has appointed Omar Abbosh, current President of Microsoft Corporation's Industry Solutions business, as its new CEO and Executive Director, effective early 2024. Abbosh will succeed Andy Bird, who is retiring. Prior to Microsoft, Abbosh held senior leadership roles at Accenture Plc. He also serves on the board of Zuora, Inc. The appointment follows a shareholder revolt over Bird's pay and concerns about the impact of AI on the business.

Portfolio Pulse from Nabaparna Bhattacharya

September 20, 2023 | 11:25 am

DB

PM

Philip Morris International Inc is considering selling a stake in its UK-based Vectura pharmaceuticals unit. The tobacco company is exploring options to make the business work, including selling a majority or minority stake, a licensing or royalties deal, or a commercial partnership. The company faced challenges over the summer, incurring a $680 million charge related to its wellness and healthcare sector. Philip Morris is reportedly in talks with Deutsche Bank AG to strategize ways to boost its wellness and healthcare unit.

Portfolio Pulse from Nabaparna Bhattacharya

September 20, 2023 | 11:18 am